0000950170-24-070966.txt : 20240607 0000950170-24-070966.hdr.sgml : 20240607 20240607183633 ACCESSION NUMBER: 0000950170-24-070966 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240607 FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Horobin Joanna CENTRAL INDEX KEY: 0001560959 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 241031072 MAIL ADDRESS: STREET 1: 215 FIRST STREET, SUITE 440 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 ownership.xml 4 X0508 4 2024-06-07 0001815442 Kymera Therapeutics, Inc. KYMR 0001560959 Horobin Joanna C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 true false false false true Common Stock 2024-06-07 4 M false 8500 2.08 A 8500 D Common Stock 2024-06-07 4 S false 2187 32.6451 D 6313 D Common Stock 2024-06-07 4 S false 6313 33.1071 D 0 D Stock Option (Right to Buy) 2.08 2024-06-07 4 M false 8500 0.00 D 2029-05-22 Common Stock 8500 33195 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 8, 2024 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.88 to $32.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.88 to $33.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of May 16, 2018, subject to the reporting person's continued employment through each vesting date. /s/ Bruce Jacobs, as Attorney-in-Fact 2024-06-07